HMH Invests in Adaptive Phage Therapeutics
December 04, 2019
Hackensack Meridian Health has invested in the clinical-stage biotechnology company Adaptive Phage Therapeutics (APT), as part of the health network’s successful innovation program, the Bear’s Den.
APT is taking aim at the toughest multi-drug resistant “superbugs” using precision-targeted, genomically-screened, and highly purified viruses known as bacteriophages, or “phages.”